Human Embryonic Stem Cells Market Size (2024 - 2029)

Human Embryonic Stem Cells Market Analysis

The human embryonic stem cell market is expected to witness a CAGR of 9.29% over the forecast period.

• The COVID-19 pandemic had a significant impact on the growth of the market, which was majorly due to the rising number of clinical trials and the growing research on stem cell therapies for effective management of COVID-19 infection. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms were focusing on effective and rapid technologies for the fast diagnosis and treatment of COVID-19. 
• For instance, according to a research article from PubMed published in April 2020, it was found that mesenchymal stem cells are safe and effective for the treatment of COVID-19. Mesenchymal Stem Cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach. The positive results from such studies led to the development of new therapies for COVID-19 and thus propelled the growth of the market. Currently, the market has reached its pre-pandemic nature and is expected to witness strong growth in the coming years.
• The growth of the market is attributed to the high prevalence of cardiac and malignant diseases, rising demand for regenerative medicines, and increasing support from government and private institutions.
• Government funding for the development of regenerative medicine has been increasing in most developed countries, owing to its applications in organ transplantation, tissue engineering, and various other applications. For instance, in June 2021, The Australian Government boosted stem cell research through USD 25 million in grants to help find and develop innovative, safe, and effective treatments for serious diseases and injuries.
• The area of human embryonic stem cell-based therapies garners significant investments, and various clinical trials that require considerable support for expenditure are currently underway. Companies are fundraising to develop stem cell-based therapies to tackle many diseases. For instance, in January 2022, Cellino Biotech, a cell therapy manufacturing company, raised USD 80 million in a Series A financing round. Cellino plans to expand access to stem cell-based therapies by building the first autonomous human cell foundry in 2025.
• Additionally, other factors, such as the high prevalence of cardiac and malignant diseases and the rising demand for regenerative medicines, are expected to drive the market. According to the data published by the European Heart Network in 2021, in the European Union, more than 60 million people live with Cardiovascular disease, and close to 13 million new cases of cardiovascular diseases are diagnosed every year. Such incidences of cardiac diseases are expected to drive the demand for effective therapeutics, such as embryonic stem cell therapies, thereby contributing to the growth of the market.
• Thus, owing to the abovementioned factors, the market is expected to project significant growth over the forecast period. However, the high cost of the procedure and stringent regulatory scenario are expected to restrain the growth of the market over the forecast period.

Human Embryonic Stem Cells Industry Segmentation

Human embryonic stem cells are pluripotent stem cells that are extracted from the inner cell mass of a blastocyst, which is an early-stage pre-implantation embryo. These stem cells are used for the treatment of various diseases. 

The human embryonic stem cells market is segmented by application (regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing) and geography (North America, Europe, Asia-Pacific, the Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. 

The report offers the value (in USD) for the above segments.